119th Congress · introduced in the Senate · Feb 11, 2025
Pharmacy Benefit Manager Transparency Act of 2025
Official title from Congress.gov
Latest action (Feb 11, 2025): Read twice and referred to the Committee on Commerce, Science, and Transportation.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Read twice and referred to the Committee on Commerce, Science, and Transportation.
Introduced in Senate
Actions from Congress.gov, newest first.
Civil actions and liability · Congressional oversight · Government information and archives · Government studies and investigations · Health care costs and insurance · Medical ethics · Prescription drugs · State and local government operations · Supply chain
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
70 citations; showing the 25 most recently posted.
NATIONAL COMMUNITY PHARMACISTS ASSOCIATION · lobbying firm or registrant: NATIONAL COMMUNITY PHARMACISTS ASSOCIATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Labor Issues/Antitrust/Workplace
$370,000
Spent on own lobbying
S.526, the Pharmacy Benefit Manager Transparency Act of 2025; S.527, the Prescription Pricing for the People Act of 2025; Comments to Department of Labor RE: "Re: Re…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$2,560,000
Spent on own lobbying
…ovation (MINI) Act ---H.R.5391/S.2764 Protecting Patient Access to Cancer and Complex Therapies Act ---H.R.9418: Access to Innovative Treatments Act of 2026 ---S.526: Pharmacy Benefit Manager Transparency Act ---S.1097: Interagency Patent Coordination and Improvement Act ---S.1954: Biosimilar Red Tape Elimination Act ---S.3…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Medicare/Medicaid
$2,560,000
Spent on own lobbying
…to Innovative Cures (EPIC) Act ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.6166: Lowering Drug Costs for American Families Act ---S.526: Pharmacy Benefit Manager Transparency Act ---S.527: Prescription Pricing for the People Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) · lobbying firm or registrant: AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Pharmacy
$3,010,000
Spent on own lobbying
…C Act - Sen. Durbin, Richard - Drug advertising requirements S. 483 - Responsibility in Drug Advertising Act - Sen. King, Angus - Drug advertising requirements S. 526 - Pharmacy Benefit Manager Transparency Act of 2025 - Sen. Grassley, Chuck - PBM reporting requirements S. 529 - Capping Prescription Costs Act - Sen. Warnock,…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF CHAIN DRUG STORES · lobbying firm or registrant: NATIONAL ASSOCIATION OF CHAIN DRUG STORES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Pharmacy
$480,000
Spent on own lobbying
…Critical Medications Act H.R. 2853 Combating Organized Retail Crime Act H.R. 3164 Ensuring Community Access to Pharmacist Services Act H.R. 4317 PBM Reform Act S. 526 Pharmacy Benefit Manager (PBM) Transparency Act S. 527 Prescription Pricing for the People Act S. 882 Patients Before Middlemen (PBM) Act S. 927 Protecting Pha…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMAC ACTION, INC. · lobbying firm or registrant: SCHOENING STRATEGIES, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$40,000
Paid to lobbying firm
Pharmacy Benefit Manager Transparency Act of 2025 - S.526; Credit for Caring Act of 2025 - H.R. 2036.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN BENEFITS COUNCIL · lobbying firm or registrant: AMERICAN BENEFITS COUNCIL
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$280,000
Spent on own lobbying
…transparency, prescription drug price transparency, PBM price transparency, hospital price transparency ERISA fiduciary duties for health care plans (S. 3345 / S. 526) Prescription Drug Data Collection reporting Medicare Operations Rule
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN MEDICAL ASSOCIATION · lobbying firm or registrant: AMERICAN MEDICAL ASSOCIATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Pharmacy
$4,540,000
Spent on own lobbying
S. 3014 - Ensuring Timely Access to Generics Act S.3822 - Break Up Big Medicine Act, all provisions S.526 - Pharmacy Benefit Manager Transparency Act of 2025, all provisions S.527 - Prescription Pricing for the People Act of 2025, all provisions Matters related to…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
INDEPENDENT PHARMACY COOPERATIVE · lobbying firm or registrant: INDEPENDENT PHARMACY COOPERATIVE
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 8, 2026 · issue area: Pharmacy
$30,000
Spent on own lobbying
IPC supports S. 526 Pharmacy Benefit Manager Transparency Act of 2025 IPC supports S. 527 "Prescription Pricing for People Act of 2025 IPC supports H.R. 4317/S.3345 PBM Reform Act…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN BENEFITS COUNCIL · lobbying firm or registrant: AMERICAN BENEFITS COUNCIL
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · amended · posted Sep 10, 2026 · issue area: Health Issues
$270,000
Spent on own lobbying
…rice transparency, Pharmacy Benefit Manufacturer (PBM) price transparency, hospital price transparency, ERISA fiduciary duties for health care plans, (S. 3345, S. 526) Hospital consolidation and billing practices, site neutral payment reform, anti-competitive practices (S. 2497) Healthy Competition for Better Care Act (HR 62…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Health Issues
$2,360,000
Spent on own lobbying
…Pricing ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.5391/S.2764 Protecting Patient Access to Cancer and Complex Therapies Act ---S.526: Pharmacy Benefit Manager Transparency Act ---S.527: Prescription Pricing for the People Act ---S.832: Ensuring Pathways to Innovative Cures (EPIC) Act ---S.10…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Medicare/Medicaid
$2,360,000
Spent on own lobbying
…IC) Act ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.5391/S.2764: Protecting Patient Access to Cancer and Complex Therapies Act ---S.526: Pharmacy Benefit Manager Transparency Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---CMMI: GLOBE and GUARD Models ---CMMI Author…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) · lobbying firm or registrant: AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Pharmacy
$3,010,000
Spent on own lobbying
…C Act - Sen. Durbin, Richard - Drug advertising requirements S. 483 - Responsibility in Drug Advertising Act - Sen. King, Angus - Drug advertising requirements S. 526 - Pharmacy Benefit Manager Transparency Act of 2025 - Sen. Grassley, Chuck - PBM reporting requirements S. 529 - Capping Prescription Costs Act - Sen. Warnock,…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF CHAIN DRUG STORES · lobbying firm or registrant: NATIONAL ASSOCIATION OF CHAIN DRUG STORES
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Pharmacy
$290,000
Spent on own lobbying
…Critical Medications Act H.R. 2853 Combating Organized Retail Crime Act H.R. 3164 Ensuring Community Access to Pharmacist Services Act H.R. 4317 PBM Reform Act S. 526 Pharmacy Benefit Manager (PBM) Transparency Act S. 527 Prescription Pricing for the People Act S. 882 Patients Before Middlemen (PBM) Act S. 927 Protecting Pha…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ALZHEIMER'S ASSOCIATION · lobbying firm or registrant: ALZHEIMER'S ASSOCIATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$1,800,000
Spent on own lobbying
…nd Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779) Better Empowerment Now to Enhance Framework and Improve Treatments (BENEFIT) Act of 2023(S. 526/H.R. 1092) Essential Caregivers Act (H.R. 6766) Ensuring Patient Access to Critical Breakthrough Products Act (S. 1717/H.R. 5343) The Reforming and Enhancing S…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN MEDICAL ASSOCIATION · lobbying firm or registrant: AMERICAN MEDICAL ASSOCIATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · amended · posted Jul 20, 2026 · issue area: Pharmacy
$5,130,000
Spent on own lobbying
S.3822 - Break Up Big Medicine Act, all provisions S.526 - Pharmacy Benefit Manager Transparency Act of 2025, all provisions S.527 - Prescription Pricing for the People Act of 2025, all provisions Draft: Removal of o…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL COMMUNITY PHARMACISTS ASSOCIATION · lobbying firm or registrant: NATIONAL COMMUNITY PHARMACISTS ASSOCIATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Labor Issues/Antitrust/Workplace
$270,000
Spent on own lobbying
S.526, the Pharmacy Benefit Manager Transparency Act of 2025; S.527, the Prescription Pricing for the People Act of 2025; Comments to Department of Labor RE: "Re: Re…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
INDEPENDENT PHARMACY COOPERATIVE · lobbying firm or registrant: INDEPENDENT PHARMACY COOPERATIVE
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 14, 2026 · issue area: Pharmacy
$40,000
Spent on own lobbying
IPC supports S. 526 Pharmacy Benefit Manager Transparency Act of 2025 IPC supports S. 527 "Prescription Pricing for People Act of 2025 IPC supports S. 882 Patients Before Middleme…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMAC ACTION, INC. · lobbying firm or registrant: SCHOENING STRATEGIES, LLC
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 10, 2026 · issue area: Health Issues
$40,000
Paid to lobbying firm
Pharmacy Benefit Manager Transparency Act of 2025 - S.526; Credit for Caring Act of 2025 - H.R. 2036.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ALZHEIMER'S ASSOCIATION · lobbying firm or registrant: ALZHEIMER'S ASSOCIATION
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · amended · posted May 20, 2026 · issue area: Health Issues
$1,790,000
Spent on own lobbying
…novation in Neurological Science (HEALTHY BRAINS) Act (H.R. 9233) Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2023 (BENEFIT) Act (S. 526/H.R. 1092) Essential Caregivers Act of 2024 (S. 4280/H.R. 8331) Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) Linking Seniors to Ne…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN PHARMACIES, INC. · lobbying firm or registrant: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 22, 2026 · issue area: Pharmacy
$60,000
Paid to lobbying firm
Issues related to independent pharmacy, including insurance coverage, network, and reimbursement; S. 526, Pharmacy Benefit Transparency Act; H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) · lobbying firm or registrant: AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Pharmacy
$5,320,000
Spent on own lobbying
…C Act - Sen. Durbin, Richard - Drug advertising requirements S. 483 - Responsibility in Drug Advertising Act - Sen. King, Angus - Drug advertising requirements S. 526 - Pharmacy Benefit Manager Transparency Act of 2025 - Sen. Grassley, Chuck - PBM reporting requirements S. 529 - Capping Prescription Costs Act - Sen. Warnock,…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · lobbying firm or registrant: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · amended · posted Apr 20, 2026 · issue area: Pharmacy
$1,670,000
Spent on own lobbying
"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · lobbying firm or registrant: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Pharmacy
$3,490,000
Spent on own lobbying
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMAC ACTION, INC. · lobbying firm or registrant: SCHOENING STRATEGIES, LLC
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$40,000
Paid to lobbying firm
Pharmacy Benefit Manager Transparency Act of 2025 - S.526; Credit for Caring Act of 2025 - H.R. 2036.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing